Exhibit 107

Calculation of Filing Fee Tables

FORM F-4

(Form Type)

CASI Pharmaceuticals Holdings, Inc.

(Exact name of Registrant as specified in its charter)

Table 1: Newly Registered Securities

	Security Type	Security Class Title	Fee Calculation Rule	Amount Registered			Proposed Maximum Offering Price Per Share of Common Stock(3)	Maximum Aggregate Offering Price(3)			Fee Rate		Amount of Registration Fee
Fees to Be Paid	Equity	Ordinary Shares, par value US$0.0001 per share (1)	457(f)		13,733,459	(2)	N/A	$	27,947,589.07	(3)		0.0001102	$	3,079.82
Fees Previously Paid	—	—	—		—		—		—					—
Carry Forward Securities
Carry Forward Securities	—	—	—		—				—			—
Total Offering Amounts								$	27,947,589.07				$	3,079.82
Total Fee Offsets														—
Net Fee Due													$	3,079.82

(1)	Relates to ordinary shares of CASI Pharmaceuticals Holdings, Inc., to be issued in connection with the Redomicile Merger described in this registration statement
(2)	Represents the maximum number of shares expected to be issued by the registrant to the stockholders of CASI Pharmaceuticals, Inc., a Delaware corporation (“CASI”), in the Redomicile Merger.
(3)	Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and (f) under the Securities Act of 1933, as amended (the “Securities Act”), based upon a market value of $2.0350 for each share of common stock of CASI, which is the average high and low sale price of CASI’s shares of common stock, as reported on the Nasdaq on January 27, 2023. In connection with the Redomicile Transaction, each CASI’s share of common stock and preferred stock will be converted into the right to receive CASI Cayman’s one ordinary share.